RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Calcitonin-gene-related peptide (CGRP) and adrenomedullin are related peptides with distinct pharmacological profiles. Here we show that a receptor with seven transmembrane domains, the calcitonin-receptor-like receptor (CRLR), can function as either a CGRP receptor or an adrenomedullin receptor, depending on which members of a new family of single-transmembrane-domain proteins, which we have called receptor-activity-modifying proteins or RAMPs, are expressed. RAMPs are required to transport CRLR to the plasma membrane. RAMP1 presents the receptor at the cell surface as a mature glycoprotein and a CGRP receptor. RAMP2-transported receptors are core-glycosylated and are adrenomedullin receptors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For several years, CRLR was an”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [146]
In the citing paper
“Dimerization of CRLR with RAMP1 forms a specific, highaffinity receptor for CGRP, whereas CRLR dimerization with either RAMP2 or RAMP3 produces receptors with high affinity to adrenomedullin (146).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [146]
In the citing paper
“CRLR by itself cannot function as a receptor for CGRP as it needs to form complexes with accessory proteins from the RAMP family134.”
From Neuropeptides Substance P and Calcitonin Gene Related Peptide Accelerate the Development and Fibrogenesis of Endometriosis (2019) · cites this paper as [134]
In the citing paper
“while for CGRP, its major receptors are calcitonin receptor like receptor (CRLR) and receptor activity modifying protein 1 (RAMP-1).”
From Neuropeptides Substance P and Calcitonin Gene Related Peptide Accelerate the Development and Fibrogenesis of Endometriosis (2019) · cites this paper as [134]
Citations
Cites
Ponath, P. D., Qin, S., Post, T. W., Wang, J., Wu, L., Gerard, N. P., Newman, W., Gerard, C., & Mackay, C. R. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.6.2437 · Cited by 612 · cited 1×
“Many receptors are not easily expressed in commonly used host cell lines: GABA b , eotaxin (CKR3”
BackgroundChang, C.-P., Pearse, R. V., O'Connell, S., & Rosenfeld, M. G. (1993) · Neuron · doi:10.1016/0896-6273(93)90230-o · Cited by 537
Teasdale, R. D., & Jackson, M. R. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.27 · Cited by 500 · cited 1×
“This pair of basic residues is similar to an endoplasmic-reticulum-retrieval moti”
BackgroundExpression Cloning of an Adenylate Cyclase-Coupled Calcitonin Receptor
Lin, H. Y., Harris, T. L., Flannery, M. S., Aruffo, A., Kaji, E. H., Gorn, A., Kolakowski, L. F., Lodish, H. F., & Goldring, S. R. (1991) · Science · doi:10.1126/science.1658940 · Cited by 451
A cDNA Encoding the Calcitonin Gene-related Peptide Type 1 Receptor
Aiyar, N., Rand, K., Elshourbagy, N. A., Zeng, Z., Adamou, J. E., Bergsma, D. J., & Li, Y. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.19.11325 · Cited by 320
Cloning and Expression of cDNA Encoding a Rat Adrenomedullin Receptor
Kapas, S., Catt, K. J., & Clark, A. J. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25344 · Cited by 288 · cited 1×
“Two related members of the ‘family A’ class of GPCRs, RDC1 and G10D, were then identified as receptors for CGRP and ADM, respectivel”
BackgroundCalcitonin gene-related peptide: Multiple actions, multiple receptors
Poyner, D. R. (1992) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(92)90036-y · Cited by 225 · cited 1×
“These activities include the regulation of neuromuscular junctions, of antigen presentation within the immune system, of vascular tone and of sensory neurotransmissio”
BackgroundWang, X., Yue, T. L., Barone, F. C., White, R. F., Clark, R. K., Willette, R. N., Sulpizio, A. C., Aiyar, N. V., Ruffolo, R. R., & Feuerstein, G. Z. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11480 · Cited by 191 · cited 1×
“and its messenger RNA is upregulated in CNS tissues that are subject to ischaemi”
BackgroundIdentification of an Orphan Receptor Gene as a Type 1 Calcitonin Gene-Related Peptide Receptor
Kapas, S., & Clark, A. J. L. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2847 · Cited by 175
Muff, R., Born, W., & Fischer, J. A. (1995) · European Journal of Endocrinology · doi:10.1530/eje.0.1330017 · Cited by 155
Cited by
Items 601–700 of 1,009
G Protein–Coupled Receptor Signaling: New Insights Define Cellular Nanodomains
Lohse, M. J., Böck, A., & Zaccolo, M. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-040623-115054 · Cited by 63
Huang, J., Stohl, L. L., Zhou, X. K., Ding, W., & Granstein, R. D. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.02.007 · Cited by 59
“…three RAMPs that have been studied, the RAMP1/CL complex demonstrates the highest affinity for CGRP, while both RAMP2 and RAMP3 complexed receptors serve as functional AM receptors with RAMP3 having limited affinity for CGRP (McLatchie et al., 1998; Kamitani et al., 1999; Nikitenko et al., 2006).”
BackgroundConsonni, A., Morara, S., Codazzi, F., Grohovaz, F., & Zacchetti, D. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2011.07.006 · Cited by 60
Adrenomedullin Function in Vascular Endothelial Cells: Insights from Genetic Mouse Models
Karpinich, N. O., Hoopes, S. L., Kechele, D. O., Lenhart, P., & Caron, K. M. (2011) · Current Hypertension Reviews · doi:10.2174/157340211799304761 · Cited by 60
“The discovery of a novel class of GPCR associated proteins called receptor activity-modifying proteins (gene=Ramp; protein=RAMP) [7] provided insight into how GPCRs signal.”
BackgroundEnhancement of the surface expression of G protein-coupled receptors
Dunham, J. H., & Hall, R. A. (2009) · Trends in biotechnology · doi:10.1016/j.tibtech.2009.06.005 · Cited by 63
CRF binding protein facilitates the presence of CRF type 2α receptor on the cell surface
Slater, P. G., Cerda, C. A., Pereira, L. A., Andrés, M. E., & Gysling, K. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1523745113 · Cited by 52
“For instance, the receptor activity-modifying protein 2 (RAMP2) increases CRF1R (28) and RAMP1 increases calcitonin-receptor-like receptor (CRLR) (29) in the plasma membrane.”
BackgroundMethodInfluentialGhanizada, H., Al‐Karagholi, M. A., Arngrim, N., Mørch‐Rasmussen, M., Walker, C. S., Hay, D. L., & Ashina, M. (2021) · Neurology · doi:10.1212/wnl.0000000000011930 · Cited by 56
“However, AM overall has a lower affinity than CGRP at the CGRP receptor.(42) Both peptides can induce facial flushing and dilate extracerebral arteries.”
BackgroundAdrenomedullin: molecular mechanisms and its role in cardiac disease
Yanagawa, B., & Nagaya, N. (2006) · Amino Acids · doi:10.1007/s00726-005-0279-5 · Cited by 61
Achour, L., Scott, M. G. H., Shirvani, H., Thuret, A., Bismuth, G., Labbé‐Jullié, C., & Marullo, S. (2008) · Blood · doi:10.1182/blood-2008-02-141275 · Cited by 58
Tam, C. W., Husmann, K., Clark, N. C., Clark, J. E., Lazar, Z., Ittner, L. M., Götz, J., Douglas, G., Grant, A. D., Sugden, D., et al. (2006) · Circulation Research · doi:10.1161/01.res.0000200737.63865.58 · Cited by 54
Minireview: Diversity and Complexity of Signaling through Peptidergic G Protein-Coupled Receptors
Rashid, A. J., O’Dowd, B. F., & George, S. R. (2004) · Endocrinology · doi:10.1210/en.2004-0052 · Cited by 55
“Oligomerization of CRLR with RAMP1 results in a complex that serves as a receptor for calcitonin gene-related peptide and oligomerization of CRLR with RAMP2 forms a functional receptor for the related ligand adrenomedullin (91).”
BackgroundGranholm, S., Lundberg, P., & Lerner, U. H. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21674 · Cited by 54
“Alpha-Minimal Essential Medium (a-MEM), HEPES-buffered a-MEM, L-glutamine, and all oligonucleotide primers were purchased from Invitrogen, Lidingö, Sweden; fetal bovine serum (FBS) from Bio Whittaker Europe, Verviers, Belgium (BMM); bensyl penicillin from AstraZeneca AB, Södertälje, Sweden; recombinant murine M-CSF…”
BackgroundInfluentialA Potential Role for Adrenomedullin as a Local Regulator of Bone Growth1
Naot, D., Callon, K. E., Grey, A., Cooper, G. J. S., Reid, I. R., & Cornish, J. (2001) · Endocrinology · doi:10.1210/endo.142.5.8152 · Cited by 54
“In addition, the combination of CRLR with RAMP1 forms a potential CGRP-specific receptor (16).”
BackgroundChapter 1 Trophic Factors in the Carotid Body
Porzionato, A., Macchi, V., Parenti, A. R., & De, R. (2008) · International review of cytology · doi:10.1016/s1937-6448(08)01001-0 · Cited by 58
Sandoval-Talamantes, A. K., Gómez-González, B. A., Uriarte-Mayorga, D. F., Martinez-Guzman, M. A., Hidalgo, K. A. W., & Alvarado‐Navarro, A. (2019) · Neuropeptides · doi:10.1016/j.npep.2019.102004 · Cited by 59
Distinct Patterns of Internalization of Different Calcitonin Gene-Related Peptide Receptors
Gingell, J. J., Rees, T. A., Hendrikse, E. R., Siow, A., Rennison, D., Scotter, J., Harris, P. W. R., Brimble, M. A., Walker, C. S., & Hay, D. L. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00089 · Cited by 54
Characterisation of CGRP receptors in the human isolated middle meningeal artery
Gupta, S. K., Mehrotra, S., Avezaat, C. J. J., Villalón, C. M., Saxena, P. R., & MaassenVanDenBrink, A. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.01.003 · Cited by 54
Hasbak, P., Opgaard, O. S., Eskesen, K., Schifter, S., Arendrup, H. C., Longmore, J., & Edvinsson, L. I. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037754 · Cited by 55
“RAMPs are proteins identified within the last few years (McLatchie et al., 1998), and they are present in various tissues such as human myocardium (Saetrum et al.”
BackgroundInfluentialMoreno, M., Terrón, J. A., Stanimirovic, D. B., Doods, H., & Hamel, É. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(01)00176-9 · Cited by 54
Fitzsimmons, T. J., Zhao, X., & Wank, S. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211946200 · Cited by 54
Aldecoa, A., Gujer, R., Fischer, J. A., & Born, W. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01387-9 · Cited by 54
The neuropeptide landscape of human prefrontal cortex
Zhong, W., Barde, S., Mitsios, N., Adori, C., Oksvold, P., Feilitzen, K. V., O’Leary, L., Csiba, L., Hortobágyi, T., Szocsics, P., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2123146119 · Cited by 51
“(24) in relation to the receptor for CGRP, the calcitonin-like receptor, are also ‘used’ in other combinations.”
BackgroundElucidating the Interactome of G Protein-Coupled Receptors and Receptor Activity-Modifying Proteins
Kotliar, I. B., Lorenzen, E., Schwenk, J. M., Hay, D. L., & Sakmar, T. P. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000180 · Cited by 56
“…proteins that are ubiquitously expressed in human tissues and unique to vertebrates, indicating that they are likely to be a relatively recent evolutionary development (McLatchie et al., 1998; Parameswaran and Spielman, 2006; GTEx Consortium, 2015; Uhl (cid:2) en et al., 2015; Klein et al., 2016).”
BackgroundInfluentialMcDonald, I. M., Austin, C., Buck, I. M., Dunstone, D. J., Gaffen, J. D., Griffin, E. P., Harper, E. A., Hull, R. A. D., Kalindjian, S. B., Linney, I. D., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0707626 · Cited by 53
Association study of calcitonin-receptor-like receptor gene in essential hypertension
SANO, M., Kuroi, N., NAKAYAMA, T., SATO, N., Izumi, Y., Soma, M., & Kokubun, S. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.10.016 · Cited by 54
Chattergoon, N. N., D’Souza, F. M., Deng, W., Chen, H., Hyman, A. L., Kadowitz, P. J., & Jeter, J. R. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00064.2004 · Cited by 53
“An association between RAMP1 and CRLR has been found to create a CGRP1 receptor (24, 29, 30).”
BackgroundTransmembrane Signaling by G Protein–Coupled Receptors
Jacob, C., & Bunnett, N. W. (2006) · Elsevier eBooks · doi:10.1016/b978-012088394-3/50006-4 · Cited by 54
Adrenomedullin binding protein-1 modulates vascular responsiveness to adrenomedullin in late sepsis
Zhou, M., Ba, Z. F., Chaudry, I. H., & Wang, P. (2002) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00544.2001 · Cited by 53
“The PCR was conducted at 30 cycles for CRLR and RAMP-3 and 25 cycles for RAMP-2.”
MethodInfluentialDexamethasone Increases RAMP1 and CRLR mRNA Expressions in Human Vascular Smooth Muscle Cells
Frayon, S., Cueille, C., Gnidehou, S., de Vernejoul, M. C., & Garel, J. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2552 · Cited by 57
Influence of G Protein Type on Agonist Efficacy
Yang, Q., & Lanier, S. M. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.3.651 · Cited by 53
Sueur, S., Pesant, M., Rochette, L., & Connat, J. (2005) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2005.09.008 · Cited by 54
Maudsley, S. R., Martin, B., & Luttrell, L. M. (2007) · Current Alzheimer Research · doi:10.2174/156720507779939850 · Cited by 54
“The pharmacology of at least two neuronally expressed GPCRs is determined not exclusively by the structure of receptor alone, but by their interaction with the non-receptor RAMP (Receptor Activity Modifying Protein) and RCP (Receptor Component Protein) proteins [74, 75].”
BackgroundRay, K. (2015) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2015.02.006 · Cited by 52
“RAMPS (RAMP1, RAMP2, and RAMP 3) are single transmembrane spanning GPCR accessory proteins that function to modify the expression and pharmacology of calcitonin (CT) receptor and calcitonin-like receptor.(61) RAMPs appear to allosterically influence the structure of CT family receptors allowing for their terminal glyc…”
BackgroundGarcés, F., Mohr, C., Zhang, L., Huang, C.-S., Chen, Q., King, C., Xu, C., & Wang, Z. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.029 · Cited by 55
A Potential Preclinical Migraine Model: CGRP-Sensitized Mice.
Russo, A. F., Kuburas, A., Kaiser, E. A., Raddant, A. C., & Recober, A. (2009) · PubMed · Cited by 52
Martínez, A., Julián, M., Bregonzio, C., Notari, L., Moody, T. W., & Cuttitta, F. F. (2004) · Endocrinology · doi:10.1210/en.2003-1251 · Cited by 52
Berenguer‐Daizé, C., Boudouresque, F., Dussert, C., Daniel, L., Muracciole, X., Grino, M., Rossi, D., Mabrouk, K., Figarella‐Branger, D., Martin, P.-M., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210656 · Cited by 52
“AM acts through the G-protein-coupled receptor calcitonin receptor-like receptor (CRLR), with specificity for AM being conferred by the receptor activity modifying protein-2 and -3 (RAMP2 and RAMP3) (McLatchie et al., 1998).”
BackgroundZaarour, N., Demaretz, S., Defontaine, N., Mordasini, D., & Laghmani, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.000679 · Cited by 58
Harikumar, K. G., Simms, J., Christopoulos, G., Sexton, P. M., & Miller, L. J. (2009) · Biochemistry · doi:10.1021/bi901326k · Cited by 48
“Additional RAMP constructs were prepared by inserting the amino- or carboxyl-terminal YFP fragments, YFP(1-158) (YN) or YFP(159-238) (YC), respectively, into the BglII/HindIII restriction sites before the TGA stop codon.”
BackgroundMethodInfluentialLai, Y., Shaftel, S. S., Miller, J. H., Tallents, R. H., Chang, Y., Pinkert, C. A., Olschowka, J. A., Dickerson, I. M., Puzas, J. E., O'Banion, M. K., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21771 · Cited by 52
“The CGRP receptor is a trimer of proteins, consisting of the CLR and 2 accessory proteins, receptor activity–modifying protein 1 and RCP (45).”
BackgroundInfluentialGrant, A. D., Gerard, N. P., & Brain, S. D. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704485 · Cited by 55
“…mainly considered to act on CGRP receptors, formed by co-expression of the calcitonin receptor-like receptor (CRLR) with receptor-accessory-modifying protein 1 (RAMP1; McLatchie et al., 1998; Juaneda et al., 2000), and with other proteins (e.g. CGRP-Receptor Component Protein; Evans et al., 2000).”
BackgroundAdrenomedullin functions as an important tumor survival factor in human carcinogenesis
Cuttitta, F., Pío, R., Garayoa, M., Zudaire, E., Julián, M., Elsasser, T. H., Montuenga, L. M., & Martínez, A. (2002) · Microscopy Research and Technique · doi:10.1002/jemt.10059 · Cited by 52
“A third receptor system has been recently identified which represents a heterodimeric complex of the previously recognized moiety, calcitonin-receptor-like receptor (CRLR) and a newly established partner, receptor-activity-modifying proteins (RAMPs) (McLatchie et al., 1998).”
BackgroundAdrenomedullin in cultured human retinal pigment epithelial cells.
Udono, T., Takahashi, K., Nakayama, M., Murakami, O., Durlu, Y. K., Tamai, M., & Shibahara, S. (2000) · PubMed · Cited by 56
Wu, D., Eberlein, W. G., Rudolf, K. D., Engel, W. W., Hallermayer, G., & Doods, H. N. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00407-6 · Cited by 52
Regulation of adrenomedullin secretion from cultured cells
Tomoda, Y., Isumi, Y., Katafuchi, T., & Minamino, N. (2001) · Peptides · doi:10.1016/s0196-9781(01)00519-8 · Cited by 54
Wong, H. K. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i3.364 · Cited by 51
Emerging roles of adhesion G protein-coupled receptors
Rosa, M., Noel, T., Harris, M., & Ladds, G. (2021) · Biochemical Society Transactions · doi:10.1042/bst20201144 · Cited by 52
Li, R., Liao, S.-B., Chiu, P. C. N., Tam, W. W., Ho, J., Ng, E. H. Y., Ho, P. C., Yeung, W. S. B., Tang, F., & Wai Sum, O. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0273 · Cited by 51
Pioszak, A. A., & Hay, D. L. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.01.001 · Cited by 53
Dong, F., Taylor, M. M., Samson, W. K., & Ren, J. T. (2006) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01631.2005 · Cited by 51
“It is believed that the CRLR/RAMP1 complex functions as a specific CGRP receptor, whereas AM preferentially binds to CRLR/RAMP2 or CRLR/RAMP3 (8, 10).”
BackgroundThe metabotropic GABA receptor: molecular insights and their functional consequences
Blein, S., Hawrot, E., & Barlow, P. N. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000725 · Cited by 51
Nagaya, N., Okumura, H., Uematsu, M., Shimizu, W., Ono, F., Shirai, M., Mori, H., Miyatake, K., & Kangawa, K. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00548.2002 · Cited by 54
Christophe, T., Karlsson, A., Rabiet, M., Boulay, F., & Dahlgren, C. (2002) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2002.01149.x · Cited by 51
Contribution of the Spared Primary Afferent Neurons to the Pathomechanisms of Neuropathic Pain
Fukuoka, T., & Noguchi, K. (2002) · Molecular Neurobiology · doi:10.1385/mn:26:1:057 · Cited by 54
Efficacy in drug receptor theory: outdated concept or under-valued tool?
Kenakin, T. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01361-9 · Cited by 51
Human adrenomedullin gene delivery protects against cardiovascular remodeling and renal injury
Chao, J., Kato, K., Zhang, J. J., Dobrzynski, E., Wang, C., Agata, J., & Chao, L. (2001) · Peptides · doi:10.1016/s0196-9781(01)00510-1 · Cited by 52
Deficiency of RAMP1 Attenuates Antigen-Induced Airway Hyperresponsiveness in Mice
Li, M., Wetzel-Strong, S. E., Hua, X., Tilley, S. L., Oswald, E., Krummel, M. F., & Caron, K. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102356 · Cited by 50
“while the association of RAMP2 with CLR produced an AM receptor [7].”
BackgroundCoester, B., Koester-Hegmann, C., Lutz, T. A., & Le Foll, C. (2020) · Diabetes · doi:10.2337/db19-0849 · Cited by 45
“The amylin receptor consists of a core calcitonin receptor (CTRA/B), which is coupled to receptor activity–modifying proteins (RAMP1–3) (3,4).”
BackgroundCGRP as a neuropeptide in migraine: lessons from mice
Russo, A. F. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12686 · Cited by 58
Hsieh, Y., Lin, C., Chiang, H., Fu, Y., Lue, J., & Hsieh, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050805 · Cited by 53
“In cutaneous nerve terminals, CGRP was co-localized with RAMP1, a chaperone component required for a functional CGRP receptor [38].”
BackgroundREEP2 Enhances Sweet Receptor Function by Recruitment to Lipid Rafts
Ilegems, E., Iwatsuki, K., Kokrashvili, Z., Benard, O., Ninomiya, Y., & Margolskee, R. F. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.0091-10.2010 · Cited by 55
“Accessory proteins can recognize these sequences and their association with the GPCR can drive cell surface targeting either by a transport mechanism (McLatchie et al., 1998) or by masking retention motifs and releasing the target protein from the endoplasmic reticulum (Jones et al.”
BackgroundMusson, D. S., McLachlan, J. L., Sloan, A. J., Smith, A. J., & Cooper, P. R. (2009) · Biology of the Cell · doi:10.1042/bc20090122 · Cited by 51
“Our original microarray results, however, demonstrated that the ADM transcript was up-regulated in diseased pulpal tissue and that transcripts for ADM receptor components including RAMP-1, RAMP3, CRLR and the CGRP receptor (McLatchie et al., 1998; Gibbons et al., 2007) were present in healthy human pulpal tissue, alth…”
BackgroundResultInfluentialHeterodimers and family-B GPCRs: RAMPs, CGRP and adrenomedullin
Conner, A. C., Simms, J., Hay, D. L., Mahmoud, K., Howitt, S. G., Wheatley, M., & Poyner, D. R. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320843 · Cited by 50
Zhao, Y., Bell, D., Smith, L. R., Zhao, L., Devine, A. B., McHenry, E. M., Nicholls, D., & McDermott, B. J. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092783 · Cited by 50
“, 2004) at which AM also has moderate affinity (McLatchie, 1998).”
BackgroundInfluentialA new family of angiogenic factors
Martínez, A. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.04.008 · Cited by 54
Glaser, S. S., Ueno, Y., DeMorrow, S., Chiasson, V. L., Katki, K. A., Venter, J. K., Francis, H., Dickerson, I. M., DiPette, D. J., Supowit, S. C., et al. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700602 · Cited by 50
“CLR requires a receptor activity-modifying protein (RAMP) to be functionally active.(18) The RAMP family of proteins is comprised of three members: RAMP-1, -2, and -3.”
BackgroundMartínez, A., Zudaire, E., Portal‐Núñez, S., Guédez, L., Libutti, S. K., Stetler‐Stevenson, W. G., & Cuttitta, F. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0103 · Cited by 53
“Although the adrenomedullin receptor has been well characterized at the molecular level (21), the structure of the PAMP receptor is not yet available; but it has been shown that exposure of adrenal medulla cells to PAMP results in a decrease of carbachol-induced Ca(2) influx (22).”
BackgroundTokoyoda, K., Tsujikawa, K., Matsushita, H., Ono, Y., Hayashi, T., Harada, Y., Abe, R., Kubo, M., & Yamamoto, H. (2004) · International Immunology · doi:10.1093/intimm/dxh072 · Cited by 54
Lipid-facing correlated mutations and dimerization in G-protein coupled receptors
Gouldson, P. R., Dean, M. K., Snell, C. R., Bywater, R. P., Gkoutos, G. V., & Reynolds, C. A. (2001) · Protein Engineering Design and Selection · doi:10.1093/protein/14.10.759 · Cited by 55
“The role of the second receptor type in modifying the pharmacology would then become analogous to the role of RAMPs (McLatchie et al., 1998; Tilakaratne et al., 2000; Zumpe et al., 2000), which may also bind in the vicinity of helices 1/2 (Gouldson et al., 2000; Sexton,P.M., personal communication, 2001).”
BackgroundHeterodimerization of G-protein-coupled receptors in the CNS
Marshall, F. H. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00001-7 · Cited by 50
Sullivan, R., Châteauneuf, A., Coulombe, N., Kolakowski, L. F., Johnson, M. P., Hébert, T. E., Éthier, N., Belley, M. L., Metters, K. M., Abramovitz, M., et al. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39256-0 · Cited by 50
Nikitenko, L. L., Brown, N. S., Smith, D. M., MacKenzie, I. Z., Bicknell, R., & Rees, M. C. P. (2001) · MHR: Basic science of reproductive medicine · doi:10.1093/molehr/7.7.655 · Cited by 49
Topham, L., Grégoire, S., Kang, H., Salmon‐Divon, M., Lax, E., Millecamps, M., Szyf, M., & Stone, L. S. (2020) · Pain · doi:10.1097/j.pain.0000000000001917 · Cited by 52
Lu, J., Piper, S. J., Zhao, P., Miller, L. J., Wootten, D. L., & Sexton, P. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158069 · Cited by 53
Eftekhari, S., Salvatore, C., Gaspar, R. C., Roberts, R., O'Malley, S. S., Zeng, Z., & Edvinsson, L. I. (2013) · The Cerebellum · doi:10.1007/s12311-013-0509-4 · Cited by 51
“Interaction of CLR with RAMP2 or RAMP3 forms adrenomedullin receptors [20, 22].”
BackgroundDaiber, P. C., Genovese, F., Schriever, V. A., Hummel, T. R., Möhrlen, F., & Frings, S. (2012) · European Journal of Neuroscience · doi:10.1111/ejn.12066 · Cited by 49
“, 2000) and receptor activity-modifying protein 1 (RAMP1; McLatchie et al., 1998).”
BackgroundMethodCalcitonin Gene-Related Peptide Regulates Type IV Hypersensitivity through Dendritic Cell Functions
Mikami, N., Sueda, K., Yusuke, O., Otani, I., Takatsuji, M., Wada, Y., Watanabe, K., Yoshikawa, R., Nishioka, S., Hashimoto, N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086367 · Cited by 50
“Both CGRP isoforms bind to a specific receptor composed of receptor activity-modifying protein 1 (RAMP1) and calcitonin receptor-like receptor (CLR) [3].”
Adrenomedullin: Continuing to explore cardioprotection
Tsuruda, T., Kato, J., Kuwasako, K., & Kitamura, K. (2018) · Peptides · doi:10.1016/j.peptides.2018.03.012 · Cited by 49
“RAMPs were first identified as chaperons that promoted the transport of CLR to the cell surface where they form calcitonin generelated peptide (CGRP) and AM receptors [81] (Fig.”
BackgroundUsdin, T. B., Wang, T., Hoare, S. R. J., Mezey, É., & Palkovits, M. (2000) · Frontiers in Neuroendocrinology · doi:10.1006/frne.2000.0203 · Cited by 58
Vidi, P., & Watts, V. J. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.053819 · Cited by 49
“Both RAMP1 and CRLR homomers were shown to accumulate at the endoplasmic reticulum (ER) in BiFC assay, whereas CRLR/RAMP1 heteromers were localized at the plasma membrane (Héroux et al., 2007), consistent with the involvement of RAMP1 in receptor trafficking (McLatchie et al., 1998).”
BackgroundEffects of Amylin on Eating and Adiposity
Lutz, T. A. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-24716-3_10 · Cited by 49
Calcitonin Gene Family of Peptides
Becker, K. L., Müller-Stich, B. P., Nylén, E., Cohen, R., White, J. C., & Snider, R. H. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1.50137-2 · Cited by 51
Functional Signaling Biases in G Protein-Coupled Receptors: Game Theory and Receptor Dynamics
Maudsley, S. R., Patel, S., Park, S.-S., Luttrell, L. M., & Martin, B. (2012) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955712800959071 · Cited by 48
Receptor activity-modifying proteins; multifunctional G protein-coupled receptor accessory proteins
Hay, D. L., Walker, C. S., Gingell, J. J., Ladds, G., Reynolds, C. A., & Poyner, D. R. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150237 · Cited by 45
Amylin receptor ligands reduce the pathological cascade of Alzheimer's disease
Zhu, H., Xue, X., Wang, E., Wallack, M., Na, H., Hooker, J. M., Kowall, N. W., Tao, Q., Stein, T. D., Wolozin, B. L., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.03.030 · Cited by 51
“Heterodimers between the CTR and either RAMP1 or RAMP3 preferentially bind amylin, and the brain predominantly expresses both RAMP1 and RAMP3 (Christopoulos et al., 1999; McLatchie et al., 1998; Wang et al., 2017).”
BackgroundFernandez, S., Knopf, M. A., Bjork, S. K., & McGillis, J. P. (2001) · Cellular Immunology · doi:10.1006/cimm.2001.1795 · Cited by 50
LPS regulates a set of genes in primary murine macrophages by antagonising CSF-1 action
Sester, D. P., Trieu, A., Brion, K., Schroder, K., Ravasi, T., Robinson, J. A., McDonald, R. C., Ripoll, V. M., Wells, C. A., Suzuki, H., et al. (2005) · Immunobiology · doi:10.1016/j.imbio.2005.05.004 · Cited by 48
Overview of Receptor Allosterism
Gregory, K. J., Sexton, P. M., & Christopoulos, A. (2010) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0121s51 · Cited by 48
Sabharwal, R., Zhang, Z., Lu, Y., Abboud, F. M., Russo, A. F., & Chapleau, M. W. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.148171 · Cited by 48
Thota, C. (2003) · Biology of Reproduction · doi:10.1095/biolreprod.103.015628 · Cited by 48
“On the other hand, CRLR, together with either RAMP2 or RAMP3, would function as a receptor for adrenomedullin (AM) [22].”
BackgroundMethodInfluentialCalcitonin receptor-like receptor guides arterial differentiation in zebrafish
Nicoli, S., Tobia, C., Gualandi, L., Sena, G. D., & Presta, M. (2008) · Blood · doi:10.1182/blood-2007-10-118166 · Cited by 47
Adrenomedullin and pregnancy: perspectives from animal models to humans
Lenhart, P., & Caron, K. M. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.02.007 · Cited by 53
Booe, J. M., Warner, M. L., Roehrkasse, A. M., Hay, D. L., & Pioszak, A. A. (2018) · Molecular Pharmacology · doi:10.1124/mol.117.110916 · Cited by 47
Coester, B., Pence, S. W., Arrigoni, S., Boyle, C. N., Le Foll, C., & Lutz, T. A. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2019.11.036 · Cited by 46
“, 2005; Lutz, 2012), a class B1 G-protein-coupled receptor (GPCR), which heterodimerizes with one or several receptor activity-modifying proteins (RAMPs 1, 2, 3) (McLatchie et al., 1998; Qi et al., 2008) to form AMY1-3.”
BackgroundMiret, J. J., Rakhilina, L., Silverman, L., & Oehlen, B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107384200 · Cited by 46
Udawela, M., Christopoulos, G., Morfis, M. M., Christopoulos, A., Ye, S., Tilakaratne, N., & Sexton, P. M. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.024257 · Cited by 48
“RAMP3 contains a PSD-95/Discs-large/ZO-1 homology (PDZ) motif (DTLL) at the C terminus that is not present in RAMP1 or RAMP2 (McLatchie et al., 1998); in other GPCR systems, interactions with PDZ domain proteins lead to altered receptor targeting after agonist stimulation.”
BackgroundZhou, F., Filipeanu, C. M., Duvernay, M. T., & Wu, G. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2005.05.014 · Cited by 50
Parker, R. M. C., Liu, M., Eyre, H. J., Copeland, N. G., Gilbert, D. J., Crawford, J., Sutherland, G. R., Jenkins, N. A., & Herzog, H. (2000) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(00)00023-3 · Cited by 47
Li, Y., Totsune, K., Takeda, K., Furuyama, K., Shibahara, S., & Takahashi, K. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1490231 · Cited by 50
“Receptor activitymodifying protein-1, -2 and -3, which form the AM receptor or the CGRP receptor together with calcitonin receptor-like receptor ( 45 ), are expressed in adipose tissue (46).”
Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity
Eržen, S., Tonin, G., Jurišić‐Eržen, D., & Klen, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031517 · Cited by 49
“RAMP is a peptide important for transporting CTR to the cell membrane and regulating its ligand specificity [47–49].”
Background
Metadata
- Authors
- McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., & Foord, S. M.
- Corresponding author
- Foord, Steven M.
- Venue
- Nature
- Published
- 1998-05
- Volume
- 393
- Issue
- 6683
- Pages
- 333-339
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2111112233
- Cited by
- 2,134
- References
- 27
- Citations by year
- 2026: 27 · 2025: 52 · 2024: 50 · 2023: 36 · 2022: 60 · 2021: 57 · 2020: 73 · 2019: 66 · 2018: 66 · 2017: 60 · 2016: 68 · 2015: 61 · 2014: 59 · 2013: 75 · 2012: 69
- FWCI
- 40.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Open Research (University of Surrey) (submittedVersion)
- Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
- Keywords
- calcitonin receptor-like receptor, receptor activity-modifying proteins, RAMP1, RAMP2, calcitonin gene-related peptide, adrenomedullin, G protein-coupled receptors, receptor trafficking, plasma membrane transport, core glycosylation, ligand specificity, peptide receptors
- MeSH terms
- Amino Acid Sequence, Animals, Biological Transport, Calcitonin, Cell Line, Cloning, Molecular, Cross-Linking Reagents, Glycosylation, Humans, Membrane Proteins, Molecular Sequence Data, Peptides, RNA, Messenger, Tumor Cells, Cultured, Xenopus, Calcitonin Gene-Related Peptide, Gene Expression, Sequence Alignment, 3T3 Cells, Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase, Receptors, Peptide, Receptors, Calcitonin, Receptors, Calcitonin Gene-Related Peptide, Cystic Fibrosis Transmembrane Conductance Regulator, Intracellular Signaling Peptides and Proteins, Mice, Adrenomedullin, Receptor Activity-Modifying Proteins, Receptor Activity-Modifying Protein 1, Receptor Activity-Modifying Protein 2, Receptors, Adrenomedullin, Calcitonin Receptor-Like Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.